查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012070

肺炎鏈球菌疫苗市場：2026年至2032年全球市場預測（按疫苗類型、年齡層、分銷管道和最終用戶分類）

Pneumococcal Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺炎球菌疫苗市場價值將達到 124.9 億美元，到 2026 年將成長至 134.5 億美元，到 2032 年將達到 216.7 億美元，複合年成長率為 8.18%。

主要市場統計數據
基準年 2025 124.9億美元
預計年份：2026年 134.5億美元
預測年份 2032 216.7億美元
複合年成長率 (%) 8.18%

從策略觀點分析近期臨床和政策發展對現代肺炎球菌疫苗接種的優先事項和實施挑戰的影響。

肺炎鏈球菌疫苗的現狀正處於穩步的科學進步與不斷變化的公共衛生優先事項的交匯點。結合疫苗製劑的最新進展、成人和老年族群適應症的擴大，以及對預防侵襲性肺炎鏈球菌感染的重新重視，都重塑了臨床指引和疫苗接種路徑。同時，監管機構也不斷完善針對高風險族群和季節性免疫策略的建議，促使醫療機構和免疫接種計畫重新檢視其疫苗接種率政策和工作流程。

產品創新、監管調整和供應鏈現代化如何重新定義肺炎球菌疫苗的交付和臨床決策。

肺炎鏈球菌疫苗生態系統正經歷一場變革，其驅動力包括產品創新、監管改革以及供應鏈基礎設施的日益成熟。新型結合疫苗擴大了血清型覆蓋範圍，正在改變臨床決策，使以往疫苗未能充分涵蓋的成人和老年人群獲得更廣泛的保護。這一演變正促使人們從依賴單一產品轉向多種選擇，臨床醫生和保險公司必須根據臨床獲益、營運可行性和成本效益來評估這些選擇。

我們將評估貿易政策變化和關稅調整對疫苗供應鏈、採購韌性和供應連續性的下游營運影響。

近年來，為調整關稅制度和貿易立場而實施的政策措施對支撐疫苗生產和分銷的醫藥和醫療供應鏈產生了切實的影響。進口關稅、醫療原料審查程序和執法措施的變化會影響零件、低溫運輸設備及相關用品的成本基礎，進而影響公共和私人免疫項目的籌資策略。當關稅波動導致關鍵原料的到貨成本增加時，製造商和經銷商通常會透過最佳化採購、協商長期供應商合約以及加快對本地生產能力的投資來應對。

以細分為主導的框架，將疫苗類型、年齡層優先事項、通路和醫療保健環境之間的差異與營運和臨床決策聯繫起來。

精細的市場細分觀點闡明了產品特性、患者群體特徵、通路和醫療機構如何影響需求模式和專案優先事項。根據疫苗類型，對結合疫苗和多醣體疫苗的情況進行評估。結合疫苗也根據特定配方進行區分，例如PCV13、PCV15和PCV20。這些差異會影響臨床建議、預期免疫抗原性和低溫運輸處理要求。根據年齡，針對成人、兒童和老年族群制定相應的臨床和計畫策略，並考慮不同族群的易感性、合併症情況和建議的接種程序。

區域趨勢使全球主要區域內不同的醫療保健基礎設施、政策環境和交付重點保持一致，並制定相應的部署策略。

區域趨勢持續影響肺炎球菌疫苗在不同醫療體系中的引入、優先排序和資金籌措方式。在美洲，免疫規劃通常著重於涵蓋弱勢群體，同時兼顧健全的公共免疫基礎設施與多元化的支付體系。區域籌資策略、國家免疫規劃和公共衛生宣傳活動都會影響疫苗接種率和規劃設計，因此，製造商和衛生部門需要合作解決覆蓋率差異問題。

製藥公司採取的策略性措施著重於高價配方、生產韌性和證據生成，以維持其臨床和商業性意義。

肺炎鏈球菌疫苗領域的競爭格局呈現出傳統製劑與新一代製劑並存的局面，各公司致力於生命週期管理、拓展適應症以及收集上市後證據以維持其臨床意義。主要企業的策略重點包括加速開發高通量結合疫苗、加強成人適應症的監管文件以及擴大製造地以提高供應可靠性。加速產品上市並解決無菌生產瓶頸的常見策略包括與契約製造生產商合作以及投資填充和包裝能力。

採取切實可行的措施，將臨床價值和供應彈性、相關人員合作以及有針對性的獲取策略相結合，以提高疫苗計劃的有效性。

產業領導者應優先採取一系列連貫的行動，以兼顧臨床價值、供應韌性和公平取得。首先，整合產品系列決策和營運能力，確保籌資策略能反映不同配方需求、低溫運輸需求和給藥方案的差異。這種協調有助於減少營運摩擦，並支援在各種醫療環境中實現穩定的供應。其次，投資於聯合供應協議和能力建設舉措，以加強區域填充和包裝能力，從而降低進口相關波動風險，並確保及時供應。

透過採用混合方法，整合臨床證據、專家意見和營運審查，我們為利害關係人產生可操作且檢驗的見解。

本分析的調查方法結合了系統性文獻綜述、針對性專家訪談和供應鏈審查，以確保證據基礎的穩健性和透明度。同行評審的臨床研究、監管指導文件和公開的安全監測報告構成了評估臨床療效、適應症和核准後表現的基礎。來自臨床醫生、疫苗學家、供應鏈專家和衛生政策顧問的專家見解，闡明了證據如何在醫療保健機構的營運和採購決策中得到體現。

綜合結論將科學進步、監管變革和營運韌性與改善免疫接種效果的實用建議聯繫起來。

總而言之，肺炎球菌疫苗領域正從多個方面演變，包括結合製劑的科學創新、政策和指南趨勢的轉變，以及對供應鏈穩健性的日益重視。這些因素迫使相關人員重新思考產品選擇、籌資策略和交付模式，以確保臨床進展能夠轉化為對所有年齡層和醫療機構的更廣泛保護。有效的因應措施需要全面規劃，涵蓋與監管環境的協調、生產韌性以及針對高風險族群的有針對性的宣傳活動。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺炎鏈球菌疫苗市場：依疫苗類型分類

  • 結合疫苗
    • PCV13
    • PCV15
    • PCV20
  • 多醣體疫苗

第9章：肺炎鏈球菌疫苗市場：依年齡層別分類

  • 成人版
  • 兒童
  • 老年人

第10章 肺炎鏈球菌疫苗市場：依通路分類

  • 離線
  • 線上

第11章 肺炎鏈球菌疫苗市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院
  • 疫苗接種中心

第12章 肺炎鏈球菌疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺炎鏈球菌疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肺炎鏈球菌疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國肺炎鏈球菌疫苗市場

第16章：中國肺炎鏈球菌疫苗市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott
  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • BioNTech SE
  • GSK plc
  • Inventprise LLC
  • KM Biologics Co., Ltd.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK Bioscience Co., Ltd.
  • Vaxcyte Inc.
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market was valued at USD 12.49 billion in 2025 and is projected to grow to USD 13.45 billion in 2026, with a CAGR of 8.18%, reaching USD 21.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.49 billion
Estimated Year [2026] USD 13.45 billion
Forecast Year [2032] USD 21.67 billion
CAGR (%) 8.18%

A strategic orientation to recent clinical and policy advances that frame contemporary pneumococcal vaccination priorities and implementation imperatives

The pneumococcal vaccine landscape sits at the intersection of robust scientific advancement and evolving public health priorities. Recent developments in conjugate vaccine formulations, expanded licensure across adult and geriatric populations, and a renewed emphasis on preventing invasive pneumococcal disease have reshaped clinical guidelines and vaccination pathways. At the same time, regulatory bodies continue to refine recommendations for high-risk groups and seasonal immunization strategies, prompting healthcare providers and immunization programs to revisit coverage policies and operational workflows.

Across clinical and operational domains, two parallel dynamics are evident: the refinement of vaccine composition to broaden serotype coverage and a strategic push to improve equitable access through supply chain optimization and provider education. These dynamics are accompanied by intensified collaboration among manufacturers, public health agencies, and clinical societies to ensure alignment on indications, administration schedules, and post-marketing surveillance. As a result, stakeholders from procurement to point-of-care are recalibrating clinical protocols and supply arrangements to reflect both the scientific advances and the logistical realities of vaccine delivery.

For decision-makers, a clear understanding of recent clinical data, policy updates, and delivery constraints is essential. Integrating these elements supports coherent strategies for immunization program design, formulary decisions, and outreach to populations with elevated risk, thereby ensuring that clinical gains translate into measurable public health impact.

How product innovation, regulatory adaptation, and supply chain modernization are collectively redefining pneumococcal vaccine delivery and clinical decision-making

The pneumococcal vaccine ecosystem is undergoing transformative shifts driven by product innovation, regulatory recalibration, and the maturation of delivery infrastructures. Newer conjugate formulations expanding serotype coverage have altered clinical decision-making, facilitating broader protection for adults and older populations previously underserved by earlier vaccine generations. This evolution is reinforcing a transition from single-product reliance toward a diversified set of options that clinicians and payers must evaluate on the basis of clinical benefit, operational feasibility, and cost-effectiveness.

Meanwhile, regulatory pathways and advisory committee guidance are adapting to emerging evidence, creating both opportunities and operational challenges for immunization programs. Manufacturers are responding with lifecycle strategies that emphasize post-approval evidence and engagement with health authorities to secure label expansions. At the same time, distribution networks and cold chain logistics are becoming more sophisticated, integrating digital visibility tools and regional partnerships to reduce wastage and improve reach into under-immunized communities.

These shifts collectively encourage stakeholders to prioritize agile procurement, enhanced surveillance, and targeted provider education. By aligning supply strategies with clinical guidance, health systems can accelerate uptake where the public health benefit is greatest while managing the logistical complexity introduced by a broader product mix and evolving immunization schedules.

Assessing the downstream operational consequences of altered trade policies and tariff adjustments on vaccine supply chains, procurement resilience, and delivery continuity

Policy measures enacted in recent years to adjust tariff regimes and trade posture have had tangible implications for the pharmaceutical and medical supply chains that support vaccine production and distribution. Changes to import duties, review protocols for medical inputs, and enforcement practices can influence the cost base for components, cold chain equipment, and ancillary supplies, which in turn affects procurement strategies for public and private immunization programs. Where tariff shifts increase landed costs for critical inputs, manufacturers and distributors often respond by optimizing sourcing, negotiating longer-term supplier agreements, and accelerating investments in local manufacturing capabilities.

In the context of pneumococcal vaccines, the cumulative effect of tariff adjustments necessitates careful scrutiny of supply chains that span raw antigen procurement, vial and syringe suppliers, and temperature-controlled logistics providers. Health systems and manufacturers are increasingly focusing on supply diversification and onshoring initiatives to mitigate exposure to import-related cost volatility. Concurrently, procurement officers are placing greater emphasis on contractual terms that lock in supply commitments and clarify responsibility for customs-related delays.

As a result, organizations involved in vaccine delivery are revising procurement frameworks, budgeting assumptions for cold chain capacity, and contingency planning to ensure continuity of vaccination services. These adaptations underscore the importance of integrated supply chain risk management that accounts for trade policy dynamics alongside clinical and operational considerations.

A segmentation-driven framework linking vaccine type differentiation, age-specific priorities, distribution channels, and care settings to operational and clinical decision-making

A nuanced segmentation lens clarifies how product characteristics, patient demographics, distribution pathways, and care settings shape demand patterns and program priorities. Based on Vaccine Type, the landscape is evaluated across Conjugate Vaccine and Polysaccharide Vaccine, with conjugate options further differentiated by specific formulations including Pcv13, Pcv15, and Pcv20; these distinctions influence clinical recommendations, immunogenicity expectations, and cold chain handling requirements. Based on Age Group, clinical and program strategies are tailored for Adult, Children, and Geriatric cohorts given differences in susceptibility, comorbidity profiles, and recommended administration schedules.

Based on Distribution Channel, distribution dynamics vary between Offline and Online pathways, with traditional provider-administered channels remaining central to routine immunization while digital procurement and telehealth-enabled coordination are expanding access and convenience. Based on End User, program design and logistics are shaped by site-specific needs across Ambulatory Care Centers, Clinics, Hospitals, and Immunization Centers, each of which has distinct staffing models, cold storage capacity, and patient throughput patterns. Integrating these segmentation dimensions enables stakeholders to align product selection, education efforts, and logistics investments with the practical realities of each setting and population cohort.

This segmentation-driven approach facilitates targeted interventions, such as prioritizing high-valency conjugate formulations in settings serving older adults or optimizing online ordering workflows for smaller clinics, thereby improving alignment between clinical value and operational delivery.

Regional dynamics and tailored deployment strategies that reconcile diverse healthcare infrastructures, policy landscapes, and delivery priorities across major global regions

Regional dynamics continue to shape how pneumococcal vaccines are introduced, prioritized, and financed across diverse healthcare ecosystems. In the Americas, vaccination programs often balance strong public immunization infrastructure with varied payer arrangements and concentrated efforts to reach marginalized populations. Regional procurement strategies, national immunization schedules, and public health campaigns influence both uptake and program design, prompting collaboration between manufacturers and health authorities to address coverage gaps.

In Europe, Middle East & Africa, the environment is heterogeneous, with high-income health systems focusing on guideline alignment and adult immunization, while low- and middle-income settings prioritize pediatric access and cold chain expansion. Policy heterogeneity across this combined region underscores the need for adaptive distribution strategies and targeted support for regulatory harmonization and capacity building. In the Asia-Pacific region, rapid urbanization, expanding private healthcare delivery, and substantial investments in domestic manufacturing capacity are reshaping access models. Regional stakeholders are leveraging technology-enabled ordering, decentralized cold chain solutions, and partnerships to increase reach in both urban and rural settings.

Across these regions, manufacturers and public health entities must calibrate launch strategies, supply allocation, and educational outreach to reflect local regulatory processes, healthcare delivery models, and population health priorities. Such regional tailoring increases the effectiveness of immunization efforts and facilitates more efficient use of available resources.

Strategic manufacturer initiatives focusing on higher-valency formulations, manufacturing resilience, and evidence-generation to sustain clinical and commercial relevance

The competitive landscape in the pneumococcal vaccine field is characterized by a mix of legacy products and next-generation formulations, with companies focusing on lifecycle management, label expansions, and post-marketing evidence generation to sustain clinical relevance. Strategic priorities among leading manufacturers include advancing higher-valency conjugate options, strengthening regulatory dossiers for adult indications, and expanding manufacturing footprint to enhance supply reliability. Partnerships with contract manufacturers and investments in fill-and-finish capacity are common tactics to accelerate market readiness and reduce bottlenecks associated with sterile manufacturing.

In parallel, manufacturers are investing in real-world evidence programs and pharmacovigilance initiatives to support clinicians and payers in assessing comparative effectiveness and safety across populations. Engagement with advisory bodies and professional societies is central to shaping guideline updates and bolstering clinician confidence in new formulations. Commercial strategies increasingly emphasize value-based propositions that link clinical benefits with operational advantages such as reduced dosing complexity or improved stability at standard refrigeration temperatures.

For purchasers and health systems, understanding each company's manufacturing resilience, evidence-generation plans, and distribution partnerships is essential when assessing supply options. This insight helps inform procurement discussions, risk-sharing arrangements, and collaborative initiatives to expand access while maintaining consistent delivery performance.

Actionable measures for integrating clinical value with supply resilience, stakeholder engagement, and targeted access strategies to enhance vaccine program effectiveness

Industry leaders should prioritize a coherent set of actions that align clinical value, supply resilience, and equitable access. First, integrate product portfolio decisions with operational capabilities by ensuring that procurement strategies reflect differences in formulation requirements, cold chain needs, and administration schedules. This alignment reduces operational friction and supports consistent delivery across diverse care settings. Next, invest in collaborative supply agreements and capacity-building initiatives that reduce exposure to import-related volatility and strengthen regional fill-and-finish capabilities to support timely availability.

Additionally, elevate evidence synthesis and provider engagement efforts to accelerate appropriate uptake. Real-world safety and effectiveness data should be systematically collected and translated into concise clinical tools and decision aids for frontline clinicians. Strengthening partnerships with public health agencies and professional societies will facilitate guideline alignment and improve the clarity of risk-based recommendations. From a commercial perspective, consider structured contracting approaches that include performance clauses and supply continuity commitments, which can mitigate disruption risk and align incentives across stakeholders.

Finally, develop targeted outreach strategies for populations with lower uptake, leveraging digital platforms for appointment scheduling and vaccine reminders while reinforcing in-person access through community immunization centers. These combined steps will help organizations convert scientific advances into measurable improvements in population protection and program efficiency.

A mixed-methods research approach synthesizing clinical evidence, expert input, and operational review to produce actionable and validated insights for stakeholders

The research methodology underpinning this analysis combines systematic literature appraisal, targeted expert interviews, and supply chain review to ensure a robust and transparent evidence base. Peer-reviewed clinical studies, regulatory guidance documents, and publicly available safety surveillance reports formed the foundation for assessing clinical efficacy, indications, and post-authorization experience. Expert input was obtained from clinicians, vaccinologists, supply chain specialists, and health policy advisors to contextualize how evidence translates into operational and procurement decisions across care settings.

Operational insights were developed through examination of distribution channel dynamics, cold chain infrastructure reports, and procurement practice analyses, complemented by engagement with logistics providers and vaccination program managers to validate practical constraints and feasible solutions. Regulatory timelines and label expansions were reviewed to understand how product availability and indication alignment influence clinical practice. Where appropriate, triangulation of data sources and cross-validation with subject matter experts were used to resolve discrepancies and ensure analytical rigor.

This mixed-methods approach balances empirical evidence with practitioner expertise, producing actionable insights that reflect both scientific validity and the pragmatic realities of vaccine delivery and program implementation.

Integrated conclusions linking scientific advancement, regulatory evolution, and operational resilience to practical recommendations for advancing immunization outcomes

In summary, the pneumococcal vaccine environment is advancing along multiple dimensions: scientific innovation in conjugate formulations, evolving policy and guideline landscapes, and a growing emphasis on supply chain robustness. These forces are prompting stakeholders to rethink product selection, procurement strategies, and delivery models to ensure that clinical advances translate into expanded protection across age groups and care settings. Effective responses require integrated planning that spans regulatory engagement, manufacturing resilience, and targeted outreach to populations at elevated risk.

Moving from insight to action involves aligning evidence-generation with operational execution. Strengthened surveillance and real-world data programs, combined with strategic contracting and local capacity investments, can mitigate disruption risk and enhance access. At the clinical interface, continued education and clear guideline communication will be essential to harmonize practice patterns and optimize vaccine utilization across adult, pediatric, and geriatric populations. Ultimately, stakeholders that proactively coordinate clinical, commercial, and logistical strategies will be best positioned to convert recent innovations into sustained public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
    • 8.1.1. Pcv13
    • 8.1.2. Pcv15
    • 8.1.3. Pcv20
  • 8.2. Polysaccharide Vaccine

9. Pneumococcal Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Children
  • 9.3. Geriatric

10. Pneumococcal Vaccine Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Pneumococcal Vaccine Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Immunization Centers

12. Pneumococcal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pneumococcal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pneumococcal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pneumococcal Vaccine Market

16. China Pneumococcal Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott
  • 17.6. Astellas Pharma Inc.
  • 17.7. Beijing Minhai Biotechnology Co., Ltd.
  • 17.8. Bharat Biotech International Ltd.
  • 17.9. Biological E. Limited
  • 17.10. BioNTech SE
  • 17.11. GSK plc
  • 17.12. Inventprise LLC
  • 17.13. KM Biologics Co., Ltd.
  • 17.14. LG Chem Ltd.
  • 17.15. Merck & Co., Inc.
  • 17.16. Novartis AG
  • 17.17. Panacea Biotec Ltd.
  • 17.18. Pfizer Inc.
  • 17.19. Pnuvax Incorporated
  • 17.20. Sanofi S.A.
  • 17.21. Serum Institute of India Pvt. Ltd.
  • 17.22. Shenzhen Kangtai Biological Products Co., Ltd.
  • 17.23. SK Bioscience Co., Ltd.
  • 17.24. Vaxcyte Inc.
  • 17.25. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)